Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
RARE: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Acquisition or asset disposal · Financial results · Restructuring
Filed 8-K for an event or period dated 2026-10-30. Acquisition or asset disposal; Financial results; Restructuring.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-10-19. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Material agreement
Filed 8-K for an event or period dated 2026-10-08. Material agreement.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Material agreement
Filed 8-K for an event or period dated 2026-10-06. Material agreement.
1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, manufactured by Ultragenyx Pharmaceutical Inc., meets the criteria for a priority review voucher.
Public: Oct 6, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; GENGLYCOS (parisglasgene brecaparvovec-opnr)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that GENGLYCOS (parisglasgene brecaparvovec-opnr), approved on August 19, 2026, manufactured by Ultragenyx Pharmaceutical, Inc., meets the criteria for a priority review voucher.
Public: Sep 2, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Partial coverage — some requests unavailable455 of 455 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:36 PM EST
- USAspending
- Partial coverage — some requests unavailable284 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- SAM.gov
- Not connected
- Lobbying disclosures
- Partial coverage — some requests unavailable75 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:29 PM EST
- Congress.gov
- Current across tracked companies2 of 2 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:17 PM EST
- Federal Register
- Partial coverage — some requests unavailable384 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable23 of 51 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- FEC campaign finance
- Stale — refresh overdue264 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST